Quarterly and annual results disclosed under 8-K Item 2.02.
GCT Semiconductor Holding, Inc. reported first quarter ended March 31, 2026 results: revenue $1.9 million.
“Quarter 2026 Financial Results Results compare the 2026 fiscal first quarter ended March 31, 2026, to the 2025 fiscal first quarter ended March 31, 2025. • Net revenues were $1.9 million, a 287 . 1% increase from $0.5 million. • Gross margin for the three months ended March 31, 2026 increased to 49.3% compared to 17.7% in the period ended March 31, 2025,”
Mobile Infrastructure Corp reported the three months ended March 31, 2026 results: revenue $7.9 million, net income $7.8 million.
“further magnifying the disconnect between the value of our portfolio and Mobile Infrastructure’s current share price.” First Quarter 2026 Highlights ● Total revenue was $7.9 million as compared to $8.2 million in the prior-year period ● Net loss was $7.8 million as compared to $4.3 million in the prior-year period. ● NOI* was $4.6 million as compared to”
REED'S, INC. reported the three months ended March 31, 2026 results: revenue $7.1 million, net income Net loss was $6.5 million.
“handcrafted, natural ginger beverages, today announced financial results for the three months ended March 31, 2026. Q1 2026 Financial Highlights (vs. Q1 2025): ● Net sales were $7.1 million compared to $10.0 million. ● Gross profit was $0.7 million compared to $3.4 million, with gross margin of 10% compared to 34%. ● Delivery and handling costs were $2.57 per case”
Hyliion Holdings Corp. reported 2026 full year results: revenue approximately $10 million. Guidance reaffirmed.
“reaffirming 2026 revenue guidance of approximately $10 million”
Hyliion Holdings Corp. reported first quarter ended March 31, 2026 results: revenue $2.8 million.
“Hyliion recorded first-quarter 2026 revenue of $2.8 million from research and development services”
PALISADE BIO, INC. reported financial results for the first quarter ended March 31, 2026.
“On May 12, 2026, Palisade Bio, Inc. (the “Company”) issued a press release announcing its financial results for the three months ended March 31, 2026.”
MAXCYTE, INC. updated its first quarter ended March 31, 2026 guidance (reaffirmed).
“On May 12, 2026, MaxCyte, Inc. (the “ Company ”) issued a press release announcing its financial results for the quarter ended March 31, 2026.”
QUICKLOGIC Corp reported fiscal first quarter ended March 29, 2026 results: revenue $5.1 million, net income ($2.2 million), EPS ($0.13) per share.
“Total revenue from continuing operations for the first quarter of fiscal 2026 was $5.1 million, an increase of 16.8% compared with the first quarter of 2025 and an increase of 35.3% compared with the fourth quarter of 2025.”
iANTHUS CAPITAL HOLDINGS, INC. reported Q1 2026 results: revenue $33,510 (thousands), net income $(14,309) (thousands), EPS $(0.00) per share.
“Table 1: Financial Results in thousands of US$, except per share amounts (unaudited) Q1 2026 Q4 2025 Q1 2025 Revenue $ 33,510 $ 35,290 $ 38,121 Gross profit 15,921 15,085 18,878 Gross margin 47.5% 42.7% 49.5% Net income (loss) (14,309) (14,090) 5,150 Net income (loss) per share (0.00) (0.00) 0.00”
iANTHUS CAPITAL HOLDINGS, INC. reported first quarter ended March 31, 2026 results: net income Net loss of $14.3 million, EPS net loss of less than $0.00 per share.
“in accordance with U.S. generally accepted accounting principles (“GAAP”). All currency is expressed in U.S. dollars. First Quarter 2026 Financial Highlights • Revenue of $33.5 million, a sequential decrease of $1.8 million from Q4 2025, and a decrease of $4.6 million from the same quarter in the prior year. • Gross profit of $15.9 million, a sequential”
TELA Bio, Inc. reported first quarter ended March 31, 2026 results: revenue $19.1 million, net income Net loss was $12.3 million. Guidance reaffirmed.
“at the conclusion of the 2026 Annual Meeting on June 9, 2026; · Noted the U.S. commercial organization is fully staffed at planned 2026 levels; · Delivered revenue of $19.1 million in the first quarter of 2026, representing growth of 3% over the prior year period; · Accelerated European revenue growth to 41% over the prior year period, with continued”
Rezolute, Inc. reported for the three months ended March 31, 2026 results: net income $16.2 million.
“Net loss was $16.2 million for the third quarter of fiscal 2026 compared with a net loss of $18.9 million for the same period a year ago.”
Intellicheck, Inc. reported first quarter ended March 31, 2026 results: revenue $5,524,000, net income $636,000, EPS $0.03 per diluted share.
“solutions, today announced its financial results for the first quarter ended March 31, 2026. Total revenue for the first quarter ended March 31, 2026 grew 13% to a record $5,524,000 compared to $4,894,000 in the same period of 2025. First quarter SaaS revenue grew 13% and totaled $5,514,000 compared to $4,868,000 in the same period of 2025. “This quarter”
INTELLIGENT PROTECTION MANAGEMENT CORP. reported the three months ended March 31, 2026 results: revenue $6,354,751, net income $(660,214).
“solid first quarter results throughout the rest of calendar 2026.” Financial Highlights: Q1 2026 Three Months Ended March, 31 (unaudited) Change 2026 2025 $ % Total revenues $ 6,354,751 $ 5,518,038 836,713 15.2 % Loss from operations $ (768,182 ) $ (1,333,927 ) 565,745 42.4 % Net (loss) income $ (660,214 ) $ 808,530 (1,468,744 ) (181.7 )% Net cash provided by”
Public Policy Holding Company, Inc. reported the quarter ended March 31, 2026 results: revenue $50.1 million, net income $11.5 million, EPS $0.49.
“Revenue increased 27.5% over Q1 2025 to $50.1 million.”
Kura Oncology, Inc. reported first quarter ended March 31, 2026 results: revenue $5.8 million.
“identified as being incorporated therein by reference. --- EX-99.1 (EX-99.1) --- EX-99.1 Exhibit 99.1 Kura Oncology Reports FIRST Quarter 2026 Financial Results – $5.8 million in KOMZIFTITM (ziftomenib) net product revenue in first full quarter of commercialization – – Robust new patient starts and early launch dynamics, including repeat use, switching”
Lineage Cell Therapeutics, Inc. reported financial results for the quarter ended March 31, 2026.
“On May 12, 2026, Lineage Cell Therapeutics, Inc. issued a press release announcing financial results for the quarter ended March 31, 2026”
Atara Biotherapeutics, Inc. reported first quarter 2026 results: revenue $0.5 million, net income net loss of $4.1 million, EPS ($0.29) basic and diluted loss per share.
“31, 2025. • Net cash used in operating activities was $3.1 million for the first quarter 2026, as compared to $28.1 million in the same period in 2025. • Total revenues were $0.5 million for the first quarter 2026, as compared to $98.1 million for the same period in 2025. The prior ‐ year period reflects a one ‐ time acceleration of revenue recognized upon the”
Zentalis Pharmaceuticals, Inc. reported financial results for first quarter ended March 31, 2026.
“On May 12, 2026, Zentalis Pharmaceuticals, Inc. (the “Company”) announced its financial results for the quarter ended March 31, 2026”
Arteris, Inc. reported the first quarter ended March 31, 2026 results: revenue $22.9 million, net income $8.0 million or $0.17 per share. Guidance reaffirmed.
“enterprise computing, automotive, communications, industrial automation and aerospace and defense,” concluded Janac. First Quarter 2026 Financial Highlights: • Revenue of $22.9 million, up 39% year-over-year • Trailing-twelve-months variable royalties of $7.9 million, up 67% year-over-year • Annual Contract Value (ACV) plus royalties of $92.8 million, up 39%”
Lumexa Imaging Holdings, Inc. reported the first quarter ended March 31, 2026 results: revenue $252.5 million, net income $1.7 million, EPS $0.02 per share. Guidance reaffirmed.
“for patients, providers, and payors.” First Quarter 2026 Highlights: All comparisons are to the quarter ended March 31, 2025, unless otherwise noted • Consolidated revenues of $252.5 million, an increase of 3.1% from $245.0 million • System-wide revenue growth of 4.0% • Same center advanced volume growth: 5.6% for both consolidated and system-wide • Net income of”
National CineMedia, Inc. reported the second quarter of 2026 results: revenue $57.0 million to $63.0 million. Guidance initiated.
“For the second quarter of 2026, NCM LLC expects to earn total revenue of $57.0 million to $63.0 million and Adjusted OIBDA in the range of $1.0 million to $5.0 million.”
National CineMedia, Inc. reported the fiscal first quarter ended April 2, 2026 results: revenue $34.0 million, net income $28.6 million, or $0.31 net loss per diluted share.
“Total revenue for the first quarter ended April 2, 2026 decreased 2.6% to $34.0 million as compared to $34.9 million for the first quarter of 2025. Operating loss increased to $26.9 million for the first quarter of 2026 from operating loss of $23.9 million for the first quarter of 2025. Net loss decreased to $28.6 million, or $0.31 net loss per diluted share, for the first quarter of 2026 from net loss of $30.7 million, or $0.32 net loss per diluted share, for the first quarter of 2025.”
HireQuest, Inc. reported first quarter ended March 31, 2026 results: revenue $6.5 million, net income $1.6 million, EPS $0.11 per diluted share.
“in franchise royalties and $74,000 in service revenue related to MRINetwork assets which were divested on January 1, 2026. Total revenue in the first quarter of 2026 was $6.5 million compared to $7.5 million in the prior year period, a decrease of 12.7%. SG&A expenses in the first quarter of 2026 were $4.3 million compared to $5.3 million in the first quarter”
KLX Energy Services Holdings, Inc. reported First quarter ended March 31, 2026 results: revenue $145 million, net income $(24) million, EPS $(1.23).
“KLX Energy Services Holdings, Inc. (Nasdaq: KLXE) (“KLX”, the “Company”, “we”, “us” or “our”) today reported financial results for the first quarter ended March 31, 2026. First Quarter 2026 Financial and Operational Highlights • Revenue of $145 million • Net loss of $(24) million and diluted loss per share of $(1.23) • Adjusted EBITDA of $11.1 million • Net loss margin of (17)% • Adjusted EBITDA margin of 8% • Total liquidity of $48 million, consisting of approximately $6 million of cash and cash equivalents, and approximately $42 million of available borrowing capacity under the March 2026 asset-based revolving credit facility (the “ABL Facility”) borrowing base certificate, inclusive of the undrawn first-in-last-out (“FILO”) capacity”
Maze Therapeutics, Inc. reported first quarter ended March 31, 2026 results: revenue $20.0 million, net income $24.2 million, EPS $0.45 per share.
“License Revenue: License revenue was $20.0 million for the quarter ended March 31, 2026. No license revenue was recognized for the quarter ended March 31, 2025.”
RESIDEO TECHNOLOGIES, INC. reported first quarter ended April 4, 2026 results: revenue $1,912 million, net income $38 million, EPS $0.17.
“Resideo Announces First Quarter 2026 Financial Results • Net revenue of $1.91 billion, up 8% year-over-year and above the high-end of outlook range”
Nextpower Inc. reported full year for fiscal year 2026, ended March 31, 2026 results: revenue $3.56 billion. Guidance raised.
“Achieved record fiscal year revenue of $3.56 billion, an increase of 20% YoY, and increased backlog to a record level of over $5.25 billion”
Nextpower Inc. reported the fourth fiscal quarter ended March 31, 2026 results: revenue $881, net income $151, EPS $0.97. Guidance raised.
“results for the fourth quarter and full year for fiscal year 2026, ended March 31, 2026. Financial Summary (In millions, except per share) Q4 FY26 Q3 FY26 Q4 FY25 Revenue $881 $909 $924 GAAP Gross Profit $297 $288 $306 GAAP Gross Margin 33.8 % 31.7 % 33.1 % GAAP Net Income $151 $131 $158 GAAP Net Income Margin 17.1 % 14.4 % 17.1 % GAAP Diluted EPS $0.97”
NeuroPace Inc reported first quarter ended March 31, 2026 results: revenue Total revenue of $22.1 million, net income ($6.7) million. Guidance raised.
“forth by specific reference in such filing. --- EX-99 (EX-99.1) --- NeuroPace Reports First Quarter 2026 Financial Results and Raises 2026 Revenue Guidance Total revenue of $22.1 million Raises full year 2026 guidance to $99 million to $101 million, up from $98 million to $100 million previously Assumes 21% to 23% growth in core RNS ® revenue from existing”
OptimizeRx Corp reported first quarter ended March 31, 2026 results: revenue $19.8 million, net income $(0.5) million, EPS $(0.03) per share. Guidance reaffirmed.
“specific reference in such filing. --- EX-99.1 (EX-99.1) --- OptimizeRx Reports First Quarter 2026 Financial Results and Updates Fiscal Year 2026 Guidance - Q1 revenue totals $19.8 million - Q1 net loss and adjusted EBITDA came in at $(0.5) million and $3.3 million, respectively - 2026 revenue guidance updated to $95-$100 million; adjusted EBITDA guidance unchanged”
IZEA Worldwide, Inc. reported financial results for first quarter ended March 31, 2026.
“On May 12, 2026 , IZEA Worldwide, Inc. (the “Company”) issued a press release disclosing the financial results for its first quarter ended March 31, 2026.”
Evolv Technologies Holdings, Inc. reported first quarter of 2026 results: net income $(5.0) million, EPS $(0.03) per basic and diluted share. Guidance raised.
“Total revenue for the first quarter of 2026 was $46.3 million, an increase of 45% compared to $32.0 million for the first quarter of 2025.”
Electromed, Inc. reported the three months ended March 31, 2026 results: revenue $ 18.6 million, net income $ 3.0 million, or $ 0.35 per diluted share, EPS $ 0.35 per diluted share.
“today announced financial results for the three and nine months ended March 31, 2026 (“ Q3 FY 2026 ”). Q3 FY 2026 Company Highlights ● Net revenues increased 18.4% to a record $ 18.6 million in Q3 FY 2026, from $ 15.7 million in the third quarter of the prior fiscal year, led by an 18.6% increase in the core homecare market. ● Operating income increased to a record $”
Beachbody Company, Inc. reported first quarter ended March 31, 2026 results: revenue $54.3 million, net income $2.3 million.
“financial foundation that positions us to capitalize on significant growth opportunities in both nutrition and digital fitness.” First Quarter 2026 Results • Total revenue was $54.3 million compared to $72.4 million in the prior year period. o Digital revenue was $33.6 million compared to $42.9 million in the prior year period and digital subscriptions totaled 0.81”
Neurogene Inc. reported the quarter ended March 31, 2026 results: net income Net loss was $30.9 million for the three months ended March 31, 2026, compared to $22.6 million for the three months end.
“Net loss was $30.9 million for the three months ended March 31, 2026, compared to $22.6 million for the three months ended March 31, 2025.”
CAPRICOR THERAPEUTICS, INC. reported financial results for first quarter ended March 31, 2026.
“today announced its financial results for the first quarter ended March 31, 2026”
Hyperfine, Inc. reported the first quarter ended March 31, 2026 results: revenue $3.90 million, net income $8.62 million, EPS $0.09 per share. Guidance reaffirmed.
“extending the expected cash runway into 2028, and providing capital for commercial growth. First Quarter 2026 Financial Results • Revenues for the first quarter of 2026 were $3.90 million, increasing 83% compared to $2.14 million in the first quarter of 2025. • Sold 10 commercial Swoop® systems in the first quarter of 2026, compared to six in the first quarter of”
SenesTech, Inc. reported first quarter ended March 31, 2026 results: revenue $493,000.
“Q1 2026 Financial Highlights • Revenue increased 2% to $493,000 in Q1 2026 compared to $485,000 in Q1 2025, despite approximately $157,000 of reduced third-party e-commerce revenue associated with the Company’s transition from third-party e-commerce management to in-house management of Amazon sales.”
Hour Loop, Inc reported the quarter ended March 31, 2026 results: revenue $29.9 million, net income $0.82 million, EPS $0.02 per diluted share. Guidance reaffirmed.
“announces its financial and operational results for the quarter ended March 31, 2026. Financial Highlights for First Quarter of 2026: ● Net revenues increased 16% to $29.9 million, compared to $25.8 million in the year-ago period; ● Net income increased to $0.82 million, compared to $0.65 million in the year-ago period; and ● Cash used in operating”
Paysign, Inc. reported first quarter 2026 results: revenue $28.04 million, net income $5.44 million, or $0.09 per diluted share, EPS $0.09 per diluted share.
“for the life sciences industries, today announced financial results for the first quarter 2026. First Quarter 2026 Financial Highlights · First quarter 2026 revenues of $28.04 million, up 50.8% from f irst quarter 2025 · First quarter 2026 pharma revenue increased to $15.68 million, an increase of 81.9% versus f irst quarter 2025; added 45 net patient”
A.K.A. BRANDS HOLDING CORP. reported first quarter ended March 31, 2026 results: revenue $132.5 million, net income $7.1 million, EPS $0.66 per share.
“a.k.a. Brands Holding Corp. Reports First Quarter 2026 Financial Results Net Sales Increased 3% to $132.5 Million”
Jushi Holdings Inc. reported the first quarter ended March 31, 2026 results: revenue $66.4 million, net income $19.8 million.
“--- EX-99.1 (PRESS RELEASE) --- EX-99.1 2 exh_991.htm PRESS RELEASE EdgarFiling EXHIBIT 99.1 Jushi Holdings Inc. Reports First Quarter 2026 Financial Results Revenue of $66.4 million , Up 4% Year-over-Year, Driven by Strong Wholesale Growth and Benefits from Retail Expansion Gross Profit Margin Expanded 460 bps Year-Over-Year to 45.0% , Reflecting Improved”
Kyverna Therapeutics, Inc. reported financial results for first quarter ended March 31, 2026.
“On May 12, 2026, Kyverna Therapeutics, Inc. (the “Company”) issued a press release providing a business update and reporting financial results for the quarter ended March 31, 2026.”
B&G Foods, Inc. updated its Full Year Fiscal 2026 guidance (reaffirmed).
“Guidance for Full Year Fiscal 2026 ● Net sales revised to a range of $1.735 billion to $1.775 billion. ● Adjusted EBITDA revised to a range of $275.0 million to $290.0 million. ● Adjusted diluted earnings per share revised to a range of $0.575 to $0.675.”
B&G Foods, Inc. reported first quarter of 2026 results: revenue $408.9 million, net income net loss of $32.5 million, EPS $0.41 per diluted share. Guidance reaffirmed.
“and delivered 2.8% base business net sales growth.” Financial Results for First Quarter of 2026 Net sales for the first quarter of 2026 decreased $16.5 million, or 3.9%, to $408.9 million from $425.4 million for the first quarter of 2025. The decrease was primarily attributable to the Green Giant U.S. frozen, Le Sueur U.S. and Don Pepino divestitures, partially”
Digimarc CORP reported financial results for first quarter ended March 31, 2026.
“On May 12, 2026, Digimarc Corporation (the "Company") issued a press release announcing its financial results for the quarter ended March 31, 2026.”
Fold Holdings, Inc. reported the first quarter ended March 31, 2026 results: revenue $5.6 million.
“Fold Holdings, Inc. (NASDAQ: FLD) Announces First Quarter 2026 Results Revenues: $5.6 million, 21.1% YoY decrease”
Immunome Inc. reported the quarter ended March 31, 2026 results: net income net loss of $53.8 million.
“Immunome reported a net loss of $53.8 million for the quarter ended March 31, 2026.”
Bolt Biotherapeutics, Inc. reported first quarter ended March 31, 2026 results: revenue Total collaboration revenue was $26,000 for the quarter ended March 31, 2026.
“Bolt Biotherapeutics Reports First Quarter 2026 Financial Results and Provides Business Update”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.